金域醫學(603882.SH):先進製造產業投資基金二期不再參與公司非公開發行
格隆匯 11 月 18日丨金域醫學(603882.SH)公佈,鑑於資本市場環境發生變化,公司經審慎考慮,擬對公司2020年度非公開發行A股股票方案進行進一步修訂調整。此次發行特定對象調整為樑耀銘,先進製造產業投資基金二期(有限合夥)不再參與此次非公開發行。就前述調整事項,公司與樑耀銘於2020年11月18日簽署《附條件生效的股份認購協議之補充協議》,對此次非公開發行認購金額及認購數量等予以進一步明確。鑑於樑耀銘為公司實際控制人,因此上述發行對象因發行方案調整與公司簽訂補充協議構成與公司的關聯交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.